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Abstract: Attention-deficit hyperactivity disorder (ADHD) has a prevalence rate of 7%–9% in 
the general population of children. However, in children with epilepsy, ADHD has been found 
to be present in 20%–50% of patients. This paper provides a review of ADHD prevalence in 
pediatric epilepsy populations and reviews data on specific symptom presentation and attention 
deficits in patients with epilepsy. This paper also reviews evidence-based treatments for ADHD 
and specifically the treatment of ADHD as a comorbid condition in children with epilepsy.
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Introduction
Children with epilepsy (CWE) experience not only seizures but also multiple cognitive, 
behavioral, and emotional problems. One of the most common difficulties is impaired 
attention or attention-deficit hyperactivity disorder (ADHD). For this review, we have 
assessed recent reports for information on the prevalence of ADHD, potential risk 
factors for ADHD, and possible treatments for ADHD in CWE. The articles were 
identified by a search on Ovid Medline using the terms attention, hyperactivity, or 
ADHD, and epilepsy. We also scanned the references in the review articles on ADHD 
and epilepsy to find additional reports.
Attention-deficit hyperactivity disorder
ADHD is described in the Diagnostic and Statistical Manual of Mental Disorders, 
fifth edition (DSM-5),1 as a neurodevelopmental disorder associated with at least six 
symptoms of inattention and/or at least six symptoms of hyperactivity and impulsivity. 
Symptoms must be severe enough to interfere with functioning, must occur in at least 
two settings (ie, school and home), and must have an age of onset before 12 years of 
age. Diagnoses can be specified as a predominantly inattentive, predominantly hyper-
active/impulsive, or combined presentation. ADHD has a prevalence rate of ~7%–9% 
of children and 2.5%–4% of adults,2–5 with twice as many boys as girls with an ADHD 
diagnosis. There is a strong genetic component to ADHD with an elevated risk in 
first-degree relatives of a person with an ADHD diagnosis. Although environmental 
and social factors can impact symptom presentation and outcomes in ADHD, the role 
of these factors is much less significant than the contribution of genetics.6 Of note, 
in addition to some other modifiers, epilepsy is cited by the DSM-5 as a potentially 
influencing ADHD symptom.
Comorbid mental health diagnoses are common in children with ADHD, with 
disruptive behavior disorders (oppositional defiant disorder and conduct disorder) 
present in about half of the children with ADHD combined presentation.1 Specific 
learning disorders are another common comorbid condition. Anxiety disorders, 
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depressive disorders, and, in adults, substance-use disorders 
are present at a higher rate in persons with ADHD than in 
the general population.
A leading theory for ADHD proposes core deficits in 
executive functioning abilities such as working memory, self-
regulation abilities (affect, motivation, and arousal), inter-
nalization of speech, and analysis/synthesis of information.6,7 
A 2005 meta-analysis looking at executive functioning tasks 
in children with ADHD found significant impairments in 
these abilities in children with ADHD compared to peers, 
with the greatest group differences in response inhibition, 
vigilance, working memory, and planning.7 These data 
support the important role of executive function deficits in 
ADHD; however, there is some evidence that this theory 
may not provide a comprehensive explanation of causality 
in ADHD (moderate effect sizes and lack of consistent defi-
cits across all executive functions within individuals with 
ADHD).7 Executive functions may represent one of several 
neuropsychological skill deficits that may contribute to 
ADHD. Another theory has proposed that deficits in cognitive 
control operations (involving executive control processes and 
motivation or regulation processes) contribute to ADHD.8
Abnormalities in frontostriatal circuits have frequently 
been implicated in ADHD, and imaging studies have sup-
ported the presence of abnormalities in these circuits in 
persons with ADHD.9,10 However, it is likely that more wide-
spread neurological abnormalities are involved in ADHD.9 
For example, in addition to the dorsolateral prefrontal cortex 
(PFC) and caudate, research supports decreased volumes of 
the pallidum, corpus callosum, and cerebellum as consistent 
findings in ADHD.9 In addition to the findings of neuro-
logical abnormalities in persons with ADHD compared to 
controls, there is an evidence that the treatment of ADHD 
with stimulant medications can reduce or normalize these 
differences.11
ADHD in epilepsy
Analysis of data from the 2007 National Survey of Children’s 
Health found a lifetime prevalence of epilepsy/seizure disor-
der in 1% (0.06% prevalence of current epilepsy) of the US 
population of children between birth and 17 years of age.12 
CWE were more likely to have academic and social difficul-
ties compared to peers without a seizure disorder.12 
A recent population-based study of children with active 
epilepsy found that neurobehavioral comorbidities were 
present in most (80%) of the CWE.13 In addition to ADHD 
that was present in 33% of patients and will be discussed in 
detail later, 40% had an intellectual disability and 21% had 
an autism spectrum diagnosis. Another study found that CWE 
are more likely than healthy peers to have been diagnosed 
with depression, anxiety, conduct problems, developmental 
delay, and autism spectrum disorders.12
Most studies assessing the prevalence of ADHD in 
patients with epilepsy have found two to three times higher 
rates of ADHD in the epilepsy population compared to 
controls. Several population-based studies have found 
ADHD prevalence rates between 23% and 40% in patients 
with epilepsy12–14 compared to a prevalence of 6%–12% in 
controls. This finding of increased prevalence in population-
based studies suggests that referral bias (CWE possibly more 
likely to be referred for ADHD assessment) is unlikely to 
explain the increased rates of ADHD in epilepsy popula-
tions. In contrast to the higher prevalence of ADHD in boys 
compared to girls in the general population, several recent 
studies have found statistically equivalent rates of ADHD 
in boys and girls with epilepsy.15–18
There is evidence to suggest that predominantly inat-
tentive presentation of ADHD is more prevalent than com-
bined presentation in patients with epilepsy (24%–52% vs 
3%–11%, respectively15,19,20), which is different from the rates 
in the general population that indicate a greater frequency of 
combined presentation. This is consistent with the parents’ 
report of the children’s ADHD symptoms in a recent study in 
which parents of children with ADHD alone reported more 
predominant symptoms of hyperactivity and impulsivity 
compared to parents of children with ADHD and epilepsy 
who reported more problems with attention.21 However, 
Gonzalez-Heydrich et al18 found the rates of ADHD subtypes 
in an epilepsy group to be similar to the distributions in the 
general population (ie, combined presentation . inattentive 
presentation). When participants with a low intelligence 
quotient (IQ) (,80) were excluded from the analyses, ADHD 
inattentive and combined presentations were equal in preva-
lence. Sherman et al20 found that in a group of children with 
severe epilepsy, those with ADHD combined presentation 
were more likely to have generalized epilepsy, an earlier 
age of onset, and lower functioning. Thus, further research 
is needed to fully understand the potential differences in 
ADHD subtypes in epilepsy.
ADHD symptoms are frequently present at the time of, 
or before, first seizure onset, suggesting that ADHD is a 
comorbid condition and not a condition caused solely by the 
seizure disorder or treatments. Hesdorffer et al17 found that 
children with new-onset seizures were 2.5 times more likely 
to have ADHD inattentive presentation (but not combined 
presentation) than were seizure-free controls. Austin et al22 
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found a similar increased prevalence of ADHD in children 
with new-onset seizures and even higher rates in children with 
a new diagnosis but with previously unrecognized seizures.
Similar to children with ADHD and no epilepsy, the 
children with ADHD and epilepsy are at risk for addi-
tional emotional, behavioral, and cognitive problems. Few 
studies have assessed the rates of psychiatric comorbidities 
in patients with epilepsy and ADHD. Gonzalez-Heydrich 
et al18 found oppositional defiant disorder and anxiety dis-
orders to be common in CWE and ADHD but noted that the 
rates of comorbidities were similar to that seen in children 
with ADHD without epilepsy. In contrast, Reilly et al23 
noted that oppositional defiant disorder and developmental 
coordination disorder were more common in CWE and 
ADHD than in those with epilepsy alone. ADHD in CWE 
has been associated with learning difficulties.24 Hermann 
et al25 showed that children with new-onset seizures and 
ADHD had significantly more learning difficulties at base-
line and 2-year follow-up than children with seizures and no 
evidence of ADHD. Reilly et al26 found that low achieve-
ment was associated with ADHD, but after controlling for 
IQ, ADHD was no longer predictive of learning difficulties 
in CWE.
Dissecting attention difficulties in epilepsy
Neuropsychological studies suggest that sustained attention 
is more often impaired than divided or selective attention and 
complex attention more affected than simple attention in 
CWE.27–29 A review of neuropsychological studies of atten-
tion problems in epilepsy found evidence for deficits in 
sustained attention in children with complex partial seizures 
(CPSs) and benign childhood epilepsy with centrotemporal 
spikes.30 On neuropsychological measures of sustained 
attention, children with CPS and ADHD performed worse 
than children with ADHD without epilepsy.30 Children with 
CPS without a diagnosis of ADHD had performance simi-
lar to those with ADHD without epilepsy on measures of 
sustained attention.30 Sustained attention has been shown to 
be impaired when interictal right hemisphere epileptiform 
activity is present compared to those with left hemisphere dis-
charges.30 Difficulty with sustained attention has been found 
to be more impaired in children with generalized compared 
to focal seizures.31 Children with benign childhood epilepsy 
with centrotemporal spikes who have epileptiform discharges 
during sleep also have deficits in selective and divided 
attention; further, these deficits show significant improve-
ment with remission of epileptiform activity during sleep.30 
More impaired complex attention and relatively normal 
simple attention have been found in children with new-onset 
epilepsy not receiving antiepileptic drugs (AEDs)28 and in 
children with seizures and hippocampal abnormalities.29 
A population-based study of cognitive abilities in CWE found 
significant difficulties in working memory and processing 
speed compared to controls, with over half of the patients 
displaying a relative weakness in at least one of the four 
working memory subtests administered.32
Berl et al33 assessed attention with the Test of Everyday 
Attention for Children (TEA-Ch) in 75 children/teens (aged 
6–15 years) with localization-related epilepsy compared to 
age-matched controls. CWE and IQ ,70 were excluded. 
Over 90% were on AEDs. They found that CWE performed 
similar to controls on measures of simple auditory and visual 
attention; however, the CWE had slower motor speed com-
pared to controls on a simple visual attention task (ie, similar 
accuracy but slower speed). Earlier age of seizure onset was 
associated with slower motor speed. Further, CWE performed 
significantly worse than controls on tasks of complex atten-
tion with over half of the epilepsy group scoring at least one 
standard deviation below the mean of the normative sample 
for these tasks.
Bechtel and Weber21 found that children with ADHD and 
epilepsy are likely to have a similar developmental course 
of their ADHD symptoms as children with ADHD alone. 
In this study, children with ADHD and epilepsy and ADHD 
alone were assessed at ~11 and 16 years of age, and both 
groups of children had a similar and significant decline in 
ADHD symptoms at follow-up. They also showed similar 
changes on functional magnetic resonance imaging in CWE 
compared to children with ADHD. Although, a couple of 
studies have observed increased problems with attention34 
and executive functioning35 in children with frontal lobe 
seizures, most studies have not found significant differences 
in attention and executive functioning based on seizure type 
or location.15,19,36,37
Risk factors
Animal models of epilepsy suggest an association between 
ADHD-type symptoms and epilepsy. When epilepsy was 
experimentally induced in rats, half of the rats also had 
evidence of inattention and impulsivity.38 These impair-
ments were associated with suppressed noradrenergic 
transmission in the locus coeruleus. Another study found 
that frequent interictal spikes in rats were associated with 
significant inattentiveness.39 Imaging studies have suggested 
that CWE and ADHD have disruptions in gray and white 
matter in a frontostriatal-cerebellar distribution, suggesting 
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similar neurological areas to those implicated in ADHD 
without epilepsy.27
Children with complicated epilepsy have been found 
to be at higher risk for ADHD compared to those with 
uncomplicated epilepsy.40 Seizure frequency is positively 
associated with a diagnosis of ADHD,41 and symptoms 
of hyperactivity are associated with intractable epilepsy. 
ADHD combined presentation has also been associated with 
more severe seizure disorders.20 Earlier age of seizure onset 
has also been found to be associated with greater cognitive 
deficits,42 including attention.33 This could be the result of 
neuronal damage resulting from frequent seizures or seizures 
in an immature brain, the effects of AEDs,42 or an underlying 
pathology, or genetic defect, contributing to etiology for both 
seizures and cognitive/attention deficits.
There is some evidence that AEDs can contribute to 
symptoms of ADHD,42–44 with polytherapy likely resulting in 
more cognitive deficits compared to monotherapy.45,46 Of the 
AEDs, phenobarbital is particularly implicated for causing 
cognitive symptoms, including problems with attention and 
hyperactivity.42 Phenytoin, carbamazepine, and valproic acid 
can also cause some problems with attention and hyperactivity 
but to a lesser extent than those seen with barbiturates.42 
Topiramate has also been found to cause significant attention 
problems similar to those seen with valproic acid.42 Available 
data at this time suggest that gabapentin, tiagabine, vigabatrin, 
and lamotrigine have few cognitive side effects and are thus 
not likely contributing significantly to ADHD symptoms.
Psychosocial factors have also been found to play a role 
in the manifestation of ADHD symptoms in CWE but are 
not thought to play a unique role in the etiology of ADHD in 
CWE (versus in healthy children with ADHD). Family and 
behavioral variables have been found to be more strongly 
associated with attention problems than seizure variables.47 
In summary, CWE have two to three times higher rates 
of ADHD (and more frequent occurrence of predominantly 
inattentive subtypes) than their healthy peers, with neurop-
sychological testing showing impairments in sustained and 
complex attention tasks.
Treatment of ADHD in epilepsy
General considerations for treating 
children with ADHD and no history of 
seizures
When children with symptoms of ADHD require medica-
tion, current guidelines recommend starting with a trial 
of a stimulant (methylphenidate [MPH] or amphetamine 
[AMP]).48–50 Should the first stimulant not be effective, 
the alternative stimulant is used next. If stimulants are not 
effective or cause intolerable adverse effects, nonstimulants, 
including atomoxetine, alpha-2 agonists, and antidepressants, 
are employed.
Psychostimulants
Stimulants are Food and Drug Administration (FDA) 
approved in the treatment of ADHD, including MPH and 
the AMPs dextroamphetamine and mixed salt AMPs.48 Both 
MPH and AMP work through blockade of dopamine and 
noradrenaline reuptake into the neurons.51,52 Furthermore, 
AMP causes release of catecholamines.51,53 Both stimulant 
groups have been found useful in the ADHD treatment. 
Stimulants have been demonstrated to be highly efficacious 
in double-blind, placebo-controlled trials with 65%–75% 
of healthy adult and child subjects responding to stimulants 
compared to 4%–30% on placebo.48 MPH and AMPs are 
equally efficacious with a combined response rate of 85% 
when tried sequentially.34 Generally, this allows the provider 
to choose either one as first line and should this fail trialing 
the other.
Details on medication treatment for ADHD are available 
in standard references.48 Generally, patients should be started 
on a long-acting formulation to promote greater adherence 
to treatment.48,54 However, short-acting stimulants and lower 
doses are often used in children at the age of 5 years or 
younger due to higher rates of emotional adverse events and 
slower metabolism of MPH in this age range.48,55,56 Parent, 
teacher, and child ADHD scales can be used to follow 
effectiveness of the medication formulation and dosage. 
Monitoring of side effects before and during treatment 
includes insomnia, headache, appetite, weight loss/growth, 
irritability, and tics. Although there are reports suggesting 
very minimal increased risk of sudden death associated with 
stimulant use, most authorities recommend against additional 
cardiac evaluation in healthy individuals.48
Nonstimulants
Generally, it is recommended that stimulants be first line 
in treatment. The nonstimulants have a lower effect size 
than stimulants. However, there may be other concerns 
making stimulants unfavorable, such as tics, concerns for 
growth, substance issues, intolerability to stimulants, or 
health contraindications. Nonstimulants have less effect on 
appetite, growth, and sleep and may be beneficial in children 
with comorbid emotional conditions such as anxiety disorder 
or Tourette syndrome.
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Atomoxetine
Atomoxetine is a nonstimulant FDA-approved medication 
for ADHD that works by noradrenergic reuptake inhibition. 
In a study by Michelson et al,57 the effect size of atomoxetine 
in ADHD was determined to be 0.7 with the greatest effects 
starting at 6 weeks of treatment. A meta-analysis further 
looked at the efficacy of atomoxetine versus stimulants show-
ing an effect size of 0.62 compared to 0.95 for long-acting 
stimulants.48,58 In another large study, using the ADHD Rat-
ing Scale IV (ADHD-RS-IV), 45% of patients treated with 
atomoxetine demonstrated a 40% decrease in core ADHD 
symptoms.59 In addition, in children with ADHD with comor-
bid anxiety, atomoxetine has been shown to be effective in 
treating the symptoms of both ADHD and anxiety48,60 and 
may be used as a first-line treatment.
The most common adverse effects of atomoxetine are 
decreased appetite, gastrointestinal issues, and sedation. 
Much less common are reports of irritability, suicidal ide-
ation, and hepatic disease.
Alpha-2 agonists
In addition to stimulants and atomoxetine, alpha-adrenergic 
agonists – clonidine and guanfacine – are used to treat 
ADHD. In particular, the alpha-adrenergic agonists, guan-
facine extended release (Intuniv) and clonidine extended 
release (Kapvay), have been approved by the US FDA for 
the treatment of childhood ADHD as monotherapy or as an 
adjunctive treatment to stimulants. The alpha-2 adrener-
gic agonists are thought to act in ADHD through postsynaptic 
alpha-2 adrenoreceptors in the PFC.61 Similar to atomoxetine, 
the alpha-adrenergic agonists are considered less effective 
than stimulants for the treatment of ADHD; however, they 
should be considered an alternative treatment option when 
insufficient efficacy or intolerable side effects are present 
during stimulant treatment. Ruggiero et al62 performed a 
systematic review and meta-analysis of ADHD treatment 
with guanfacine versus placebo. Using seven included studies 
and 1,752 participants, they found 59% of patients benefit-
ing from treatment compared to 33.3% on placebo, and the 
most prominent side effects were noted as somnolence, 
headache, and fatigue. With regard to the side effects, guan-
facine has selectivity for alpha-2 adrenoreceptors in the PFC 
and has shown less central nervous system depressant 
and hypotensive effects than clonidine.62 Of additional 
interest, a multicenter, double-blind, placebo-controlled 
dose-optimization study of guanfacine extended release 
used as an adjunct to stimulant treatment in children with 
ADHD and comorbid oppositional symptoms demonstrated 
significant improvement in oppositional symptoms when 
compared to the combination of stimulant and placebo.63
Alternative nonstimulant medications for the child with 
ADHD and no evidence of epilepsy include the tricyclic 
antidepressants and bupropion. The effect size is low, and 
there are concerns about cardiac toxicity of tricyclic anti-
depressants and the lowering of seizure threshold with 
bupropion.
Prescribing ADHD medications for Cwe
In CWE and ADHD, there are several questions. Are the 
standard medications for ADHD effective in CWE, and if so, 
which medications are most likely to be effective. Second, are 
the standard medications for ADHD safe in CWE. Finally, 
are there additional concerns about potential adverse effects 
of ADHD medications that should be considered in CWE.
Because there are multiple causes for impaired atten-
tion in the child with epilepsy, including current seizures, 
effects of chronic seizures on cognitive functioning, AED 
side effects, and medication interactions, the provider should 
review the patient’s seizure frequency and AEDs to deter-
mine if improvements in seizure frequency could be made, 
the medication regimen is contributing to behavioral and 
attention symptoms, and/or the regimen can be simplified 
to limit drug interactions.
As seen in children with ADHD and no seizures, stimu-
lant medication appears to be effective for treatment of 
ADHD in CWE.51,64–68 The use of MPH in children with 
ADHD appears to show a 70%–80% response rate.64 In con-
trast to the robust data for the use of stimulants in the child 
with ADHD alone, the data for the treatment of ADHD in 
CWE are much weaker. There are two double-blind, placebo-
controlled trials. Feldman et al66 assessed ten children with 
multiple seizure types, no seizures in the past 3 months, 
and cognitive function ranging from disabled to normal in 
a 4-week trial of MPH, given twice daily at 0.3 mg/kg/dose 
and found that 70% improved. Gonzalez-Heydrich et al69 
studied 33 children and adolescents who had been seizure free 
for 1 month. Patients received osmotic release oral system 
MPH 18, 36, or 54 mg, or placebo for 1 week. There was a 
significant improvement in ADHD symptoms during the time 
on MPH compared to the time on placebo. Three open-label 
studies using MPH found a response rate of 70%–77%.69–71 
There is much less data on response of ADHD symptoms 
to AMPs in CWE. In one retrospective study, 12 out of 19 
patients had a favorable response to MPH compared to four 
of 17 who received AMP. Two open-label studies have 
looked at the treatment of ADHD in children and adolescents 
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with active and refractory seizure disorders. Santos et al72 
evaluated the impact of low-dose MPH (up to 1 mg/kg) on 
ADHD symptoms in 22 children with severe epilepsy and 
found that after 3 months of treatment, 73% had entered 
remission with subthreshold scores on an ADHD symptom 
questionnaire. Fosi et al treated 18 patients with refractory 
epilepsy and intellectual disability with MPH 0.3–1 mg/kg/d 
and found reduction of ADHD symptoms in 63%.73 Of note, 
the impact of MPH on ADHD symptoms does not appear 
to be affected by IQ or learning disability.72,73 In addition to 
ADHD symptom improvement, another study of MPH in 
children with difficult-to-treat epilepsy suggested a positive 
impact on quality-of-life scores related more to behavioral 
improvement than simply AED adjustment and improvement 
in seizures.74
A persistent concern with the use of stimulant medica-
tion in CWE is the risk of increase in seizure frequency. 
In the two controlled trials, there were no seizures during 
the 4-week treatment trial reported by Feldman et al,66 but 
there was a trend for more seizures during the week on the 
highest dose of osmotic release oral system MPH in the study 
of Gonzalez-Heydrich et al.69
In the open-label trial reported by Gross-Tsur et al,64 
none of the 25 children who had any seizures in the 2 months 
prior to MPH treatment had additional seizures, but three 
of five children with seizures during the lead-in period had 
an increase in seizure number. Gucuyener et al70 found no 
increase in mean seizure frequency but noted increase in 
seizure number in five of 57 patients who had seizures prior 
to starting MPH. Koneski and Casella71 found that during 
a 6-month open-label treatment with MPH, 91.6% had no 
increase in seizures; however, increased numbers were seen in 
8.3%. In the retrospective study of Gonzalez-Heydrich et al,69 
none of the 17 patients who were seizure free at the beginning 
of stimulant treatment had additional seizures, but three of 
19 patients with seizures had an increase in seizure frequency. 
In the two studies of patients with refractory epilepsy, one 
noted no deterioration in seizure control and the second found 
increased seizure frequency in four out of 22 patients.
In the literature, there is less information on efficacy and 
tolerability of AMP, atomoxetine, and alpha-2 adrenergic 
agonists in CWE. In one study, a retrospective medical 
records review allowed a comparison of MPH and AMP 
in a population of 36 CWE and ADHD treated with stimu-
lants. A higher response rate in the treatment of ADHD 
was seen in the MPH group (12/19, 63%) versus the AMP 
group (4/17, 21%). Within the group before treatment with 
stimulant, 47% were considered seizure free and 53% had 
active seizures, and there were no significant differences in 
the number of patients in each group prescribed MPH versus 
AMP. During the trial, one patient on MPH and two patients 
on AMP had increased seizure frequency that returned to 
baseline with discontinuation of stimulants.16 In a review 
of the clinical trials, database and postmarketing reported 
spontaneous adverse events, 12 out of 5,082 patients (0.2%) 
on atomoxetine had a seizure, at the same rate as placebo, 
suggesting that children taking atomoxetine for ADHD are 
not at increased risk of seizures.75 In another study by Torres 
et al,76 tolerability of atomoxetine in CWE and ADHD with 
previous treatment failure was reviewed and found that 63% 
of 27 patients discontinued treatment with the majority due 
to poor response or worsening behavior. There is a lack of 
studies reviewing alpha-2 adrenergic agonists, both in their 
impact on ADHD treatment in CWE and on their effect on 
seizures. However, there have been reports of seizures fol-
lowing clonidine ingestions (1, 126–130).77–80
There are additional considerations for using ADHD med-
ications in CWE. Tricyclic antidepressants and bupropion 
have been used in children with ADHD but can lower seizure 
threshold and should be avoided in patients with epilepsy. 
Drug interactions between medications for ADHD and AEDs 
are minimal. MPH may increase phenytoin serum levels, and 
carbamazepine may reduce MPH levels. There are no reports 
of interaction between atomoxetine or alpha adrenergics and 
AEDs. Because of the sedative effects of alpha adrenergics, 
they should be used cautiously in patients receiving sedating 
AEDs. Sudden unexpected death in patients with epilepsy 
is a concern, but there are no data to suggest that stimulant 
medications may increase the risk of sudden death associ-
ated with seizures.
Any statement about efficacy and safety of medical treat-
ment of ADHD in patients with epilepsy must acknowledge 
the major limitation in data. There are only two double-blind 
placebo-controlled trials, and one has only ten participants 
and the other limited treatment to 1 week. There are more 
open-label trials, but the number of participants in each study 
is small. Only the report by Gucuyener et al70 had .50 patients 
with epilepsy. Most studies used samples with both intel-
lectual disability and normal intelligence and with multiple 
seizure types. The samples are too small to comment on the 
effect of cognitive function or seizure type on the efficacy 
of medication for ADHD. Only the trials of MPH have suf-
ficient numbers for reasonable suggestions on efficacy and 
adverse effects. The reports on AMP and atomoxetine are 
open label and have small numbers of participants, and there 
are no reports on alpha adrenergics in CWE.
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From this review of the literature, we conclude that MPH 
is effective in the treatment of symptoms of ADHD in children 
and adolescents with seizures though the effect size is possibly 
lower than that seen in children with ADHD without epilepsy. 
AMPs and atomoxetine may be effective but with lower effect 
size and very limited data. The risk of increase in seizure fre-
quency appears to be minimal with MPH, atomoxetine, and 
the alpha adrenergics, but patients should be warned of a low 
risk of seizures and should be monitored closely.
Treatment of ADHD with behavioral 
therapies
While psychopharmacology is the primary treatment modality 
for ADHD, behavioral treatment may be recommended for 
use in combination with medication treatment or in children 
with minimal impairment or when medication is not an option 
due to contraindications or parental objections. Behavioral 
therapies would not be expected to differ significantly in 
implementation or efficacy in children with ADHD with and 
without epilepsy. However, in CWE, compared to otherwise 
healthy children with ADHD, there may be a higher likeli-
hood for medical contraindications or parental objections 
(eg, a desire to minimize the number of overall medications) 
to medication treatment of ADHD, and thus, behavioral 
therapies may present an important avenue for treatment. 
There is some evidence that behavioral therapies can be 
effective adjuncts to medication treatment or as stand-alone 
treatments for ADHD. A large randomized controlled trial 
assessing treatment efficacy (behavioral treatment, medica-
tion treatment, both medication and behavioral treatment, 
and community treatment) over a 14-month period found that 
ADHD symptoms improved in all groups with the greatest 
improvements for those in the medication only and combined 
intervention groups.81 Participants receiving both medication 
and behavioral treatment received lower doses of medications 
compared to those in medication management alone and had 
more improvement in non-ADHD symptoms (eg, oppositional 
behaviors, internalizing) compared to medication manage-
ment alone. However, there were no significant differences 
in ADHD symptoms in participants receiving combination 
treatment versus medication alone. Behavioral treatments for 
ADHD are often modeled off of the work by Barkley82 and 
typically include parent behavior training to improve the use 
of effective contingency management, reinforcement, and 
routines to target challenges associated with ADHD. Similar 
interventions are also implemented in the school setting. There 
is very limited research assessing behavioral therapies for 
ADHD in children with comorbid epilepsy. Triplett et al83 
conducted a functional magnetic resonance imaging study in 
CWE and demonstrated improvements in inhibitory control 
following reward trials. Thus, there is evidence that cognitive 
rehabilitation may be effective at targeting ADHD symptoms 
in CWE; however, further research is needed.
Conclusion
Research indicates that ADHD is more prevalent in CWE 
compared to healthy peers, with some evidence indicating that 
the inattentive presentation (as opposed to combined presenta-
tion) is more common in this population. Some aspects of the 
seizure disorder and its treatment could contribute to ADHD 
symptoms. For example, children with complicated epilepsy 
may be at greater risk for ADHD, and some antiepileptic 
medications can contribute to ADHD symptoms. However, 
the seizure disorder and its treatment are not likely the sole 
cause of increased prevalence of ADHD in this population, as 
evidenced by the increased presence of ADHD symptoms even 
before diagnosis of a seizure disorder. Research should con-
tinue to investigate the nature of the comorbidity of these two 
conditions. Many studies have demonstrated the importance of 
ADHD medication treatment both in healthy children and in 
CWE. The importance of consideration for ADHD treatment 
was recently highlighted again by a large population-based 
study by Sayal et al.84 In the study, with each one-point increase 
in inattention symptoms at 7 years old, an associated worse 
academic outcome was seen at 16 years old, demonstrating a 
long-term academic risk. While there may be some individual 
risk of increase in seizures in treated patients, the benefit of 
treatment appears to outweigh the risk. There are limitations in 
the current research of treatment for ADHD in CWE with the 
lack of larger patient studies, controlled trials, and long-term 
outcome data showing that treatment improves cognitive out-
come. Further research testing of efficacy and seizure effects 
of psychotropic medications should continue, particularly with 
regard to AMPs and the alpha-2 adrenergic agonists.
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